Bahrain Approves China’s Sinopharm Covid-19 Vaccine

Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine.

“Results from Phase III clinical trials showed an 86% efficacy rate, a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement Sunday.

Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorized the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients.

The UAE registered the Sinopharm vaccine after finding it had a 86% efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy.

Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine.

https://www.bloomberg.com/news/articles/2020-12-13/bahrain-approves-china-s-sinopharm-covid-19-vaccine

https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175

Bahrain Approves China’s Sinopharm Covid-19 Vaccine

Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine.

“Results from Phase III clinical trials showed an 86% efficacy rate, a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement Sunday.

Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorized the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients.

The UAE registered the Sinopharm vaccine after finding it had a 86% efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy.

Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine.

https://www.bloomberg.com/news/articles/2020-12-13/bahrain-approves-china-s-sinopharm-covid-19-vaccine

https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175

Bahrain Approves China’s Sinopharm Covid-19 Vaccine

Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine.

“Results from Phase III clinical trials showed an 86% efficacy rate, a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement Sunday.

Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorized the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients.

The UAE registered the Sinopharm vaccine after finding it had a 86% efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy.

Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine.

https://www.bloomberg.com/news/articles/2020-12-13/bahrain-approves-china-s-sinopharm-covid-19-vaccine

https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175

Bahrain Approves China’s Sinopharm Covid-19 Vaccine

Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine.

“Results from Phase III clinical trials showed an 86% efficacy rate, a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement Sunday.

Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorized the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients.

The UAE registered the Sinopharm vaccine after finding it had a 86% efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy.

Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine.

https://www.bloomberg.com/news/articles/2020-12-13/bahrain-approves-china-s-sinopharm-covid-19-vaccine

https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175

Bahrain Approves China’s Sinopharm Covid-19 Vaccine

Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine.

“Results from Phase III clinical trials showed an 86% efficacy rate, a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement Sunday.

Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorized the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients.

The UAE registered the Sinopharm vaccine after finding it had a 86% efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy.

Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine.

https://www.bloomberg.com/news/articles/2020-12-13/bahrain-approves-china-s-sinopharm-covid-19-vaccine

https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175

Bahrain Approves China’s Sinopharm Covid-19 Vaccine

Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine.

“Results from Phase III clinical trials showed an 86% efficacy rate, a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement Sunday.

Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorized the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients.

The UAE registered the Sinopharm vaccine after finding it had a 86% efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy.

Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine.

https://www.bloomberg.com/news/articles/2020-12-13/bahrain-approves-china-s-sinopharm-covid-19-vaccine

https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175

Bahrain Approves China’s Sinopharm Covid-19 Vaccine

Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine.

“Results from Phase III clinical trials showed an 86% efficacy rate, a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement Sunday.

Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorized the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients.

The UAE registered the Sinopharm vaccine after finding it had a 86% efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy.

Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine.

https://www.bloomberg.com/news/articles/2020-12-13/bahrain-approves-china-s-sinopharm-covid-19-vaccine

https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175

Bahrain Approves China’s Sinopharm Covid-19 Vaccine

Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine.

“Results from Phase III clinical trials showed an 86% efficacy rate, a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement Sunday.

Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorized the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients.

The UAE registered the Sinopharm vaccine after finding it had a 86% efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy.

Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine.

https://www.bloomberg.com/news/articles/2020-12-13/bahrain-approves-china-s-sinopharm-covid-19-vaccine

https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175

Bahrain Approves China’s Sinopharm Covid-19 Vaccine

Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine.

“Results from Phase III clinical trials showed an 86% efficacy rate, a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement Sunday.

Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorized the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients.

The UAE registered the Sinopharm vaccine after finding it had a 86% efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy.

Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine.

https://www.bloomberg.com/news/articles/2020-12-13/bahrain-approves-china-s-sinopharm-covid-19-vaccine

https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175

Bahrain Approves China’s Sinopharm Covid-19 Vaccine

Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine.

“Results from Phase III clinical trials showed an 86% efficacy rate, a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement Sunday.

Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorized the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients.

The UAE registered the Sinopharm vaccine after finding it had a 86% efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy.

Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine.

https://www.bloomberg.com/news/articles/2020-12-13/bahrain-approves-china-s-sinopharm-covid-19-vaccine

https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175

https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175

Bahrain Approves China’s Sinopharm Covid-19 Vaccine

Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine.

“Results from Phase III clinical trials showed an 86% efficacy rate, a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement Sunday.

Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorized the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients.

The UAE registered the Sinopharm vaccine after finding it had a 86% efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy.

Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine.

https://www.bloomberg.com/news/articles/2020-12-13/bahrain-approves-china-s-sinopharm-covid-19-vaccine

@Orlando Go back to your mom's shithole...

@Orlando = Dickhead hahahaha

@Orlando = Jutawansenyap = Jus-Aqua hahahaha

@Orlando. You are stupider than my artifical intelligence app

@otlando go back to that shithole you came out from lololol

@orlando lol that’s shows how dumb you are keep on parroting what I say to you . My artificial intelligence is smarter than you hahahaha

@UlarSawa it’s clear that you are anti-China here. So no point reasoning with you

@orlando happy to get rid of you lolol

@orlando you are the moron here haha as is said even my artificial intelligence app is smarter than you hahaha

@Orlanda Good sayonara to you....I do not welcome people like you here haha

@Bursamalaysia8888 Dude chill. we are on the same side !! My intention here was to elevate / promote China vaccine by highlighting the disadvantages of western vaccine. That was my intention here not the opposite Zzzzz

Insider news tipu one dont believe

WARNING :

For your information....GI HEALTHCARE RESOURCES SDN. BHD is not even registered for business. Just incorporated co name only.

----------------

Name: GI HEALTHCARE RESOURCES SDN. BHD.
Registration No. : 202001010663 (1366983-D)
Incorporation Date: 30-04-2020
Registration Date: Nil
Fees paid: RM 100
Share issued: Nil

Note:
This is a shelf company without any paid up capital. It is also not registered for commencement of business. The above info is obtained from SSM Company Search.

https://www.theedgemarkets.com/article/sanofi-gsk-announce-delay-covid19-vaccine-project

https://www.theedgemarkets.com/article/sanofi-gsk-announce-delay-covid19-vaccine-project

https://www.globaltimes.cn/content/1209637.shtml

Umno man tells of efforts to undo 'No Anwar, No DAP' policy

Umno's Ketereh MP Annuar Musa said there are efforts to undo the position the party has taken not to cooperate with PKR president Anwar Ibrahim and DAP.

Meanwhile, Johor Umno deputy chief Nur Jazlan Mahmed warned that Umno might ditch Perikatan Nasional and work with Harapan if Bersatu continued to make Umno play second fiddle.

"Logic dictates that the strongest party in a coalition (must) be the dominant party, whether it's via an election or deciding on the posts of prime minister, menteri besar or chief minister. We need a reset at the federal and state levels," he was quoted as saying by Free Malaysia Today.

He added the party's grassroots should explore cooperation with Harapan, including DAP.

Even though there is much animosity between Umno and DAP but electorally, DAP does not contest in most of Umno's seats as both parties serve very different demography.

In contrast, Umno has vast overlaps with Bersatu and PAS in terms of the constituencies that they want to contest as all three focus on the Malay and Muslim community.

https://malaysia.news.yahoo.com/umno-man-tells-efforts-undo-033800960.html

Wah Nur Jazlan Mohamed still so powerful speaking on behalf of UMNO. So conclusion is UMNO may decide to cooperate with PKR (Anwar) and DAP ?

-----------------

Umno may ditch PN, work with PH if PPBM’s ‘antics’ continue, says Nur Jazlan

Umno will not hesitate to ditch Perikatan Nasional (PN) and go it alone in the next general election (GE15) or even tie-up with Pakatan Harapan (PH) if PPBM continues to punch above its weight to dominate the coalition, a senior Umno leader said today.

Johor Umno deputy chief Nur Jazlan Mohamed warned the party stood to pay a heavy price if it stayed in the ruling coalition and allowed a “weak” PPBM to take the lead at the polls.

Nur Jazlan said there was “simmering frustration” among Umno members against PPBM’s attempts to impose itself as a dominant force in the PN government.

He said, looking at the situation at hand, the party’s grassroots should start thinking “broadly to understand” why the party should explore options such as cooperating with PH component parties, including DAP.

https://www.freemalaysiatoday.com/category/nation/2020/12/12/umno-may-ditch-pn-work-with-ph-if-ppbm-antics-continue-says-nur-jazlan/

PETALING JAYA: A pro-Anwar Ibrahim group has asked the PKR president to “burn” the statutory declarations (SDs) of support for him, move on and focus on the next general election (GE15).

Otai Reformis secretary Abdul Razak Ismail said this was because the opposition failed to garner enough support to oppose the budget allocations for 22 ministries in the Dewan Rakyat.

He added that Pakatan Harapan (PH) should give up hope of wresting Putrajaya from the Perikatan Nasional-led government through the support of MPs.

“When PH failed to get 15 MPs to support a request for a bloc vote on the federal budget at the policy stage, the perception was that the game was already over.

https://www.freemalaysiatoday.com/category/nation/2020/12/12/burn-the-sds-claiming-support-and-move-on-reformasi-group-tells-anwar/

Rileks... Honestly at this point, i am not bothered what Anwar says. The last time he went to Agong, nothing extraordinary happened. Subsequently, during the parliamentary debate on budget, there was no bloc vote as he didnt have the majority to support...So i am quite doubtful....

https://www.freemalaysiatoday.com/category/bahasa/tempatan/2020/12/12/peruntukan-22-kementerian-lulus-bukti-ph-gagal-dapat-sokongan-kata-otai-reformis/

Otai Reformis minta Anwar berhenti berharap dan 'move on'

https://www.malaysiakini.com/news/554962

COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports

Background: Guillain-Barre Syndrome (GBS) is a neurological autoimmune disease that can lead to respiratory failure and death. Whether COVID-19 patients are at high risk of GBS is unknown. Through a systematic review of case reports, we aimed to summarize the main features of patients with GBS and COVID-19.

GBS is emerging as a disease that may appear in COVID-19 patients. Although limited, preliminary evidence appears to suggest that GBS occurs after COVID-19 onset. Practitioners and investigators should have GBS in mind as they look after COVID-19 patients and conduct research on novel aspects of COVID-19. Comparison with GBS patients in the context of another viral outbreak (Zika), revealed similarities and differences that deserves further scrutiny and epidemiological studies.

Conclusions: GBS is emerging as a disease that may appear in COVID-19 patients. Although limited, preliminary evidence appears to suggest that GBS occurs after COVID-19 onset. Practitioners and investigators should have GBS in mind as they look after COVID-19 patients and conduct research on novel aspects of COVID-19. Comparison with GBS patients in the context of another viral outbreak (Zika), revealed similarities and differences that deserves further scrutiny and epidemiological studies.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509591/

Just my thoughts regarding one of the plausible causes of Guillain-Barre syndrome reported in that ONE volunteer in the Peru clinical trial of Sinopharm Vaccine.

It is possible that the particular volunteer contracted Covid-19 infection which led to Guillain-Barre syndrome as a complication.

-----------------

Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports

Similar to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), the coronavirus disease 2019 (COVID-19) has neurological symptoms. COVID-19 patients have such clinical symptoms as headache, vomiting, nausea, dizziness, myalgia, anosmia, ageusia, and disorder of consciousness. These symptoms confirm that the nervous system is involved in the COVID-19 infection. Guillain-Barré syndrome (GBS) is a heterogeneous disorder which often follows a viral infection. According to the assessment case reports from the beginning of the COVID-19 infection so far, it is possible that GBS is linked to the COVID-19 infection. It seems that paying attention to the neurological effects of COVID-19 is necessary.

According to the case reports from around the world, it is possible that GBS is linked to the COVID-19 infection. However, more cases with epidemiological data should be studied and future investigations should be carried out in this regard. Due to the possible association of GBS and COVID-19, it is recommended that the patients be followed up by physicians with respect to neurological manifestations. Finally, it is suggested that research on the relationship between COVID-19 and the nervous system be not limited to the current period so that if we encounter a new type of this virus in the future, the necessary measures could be taken.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464053/

Sanofi suffers major setback in development of a Covid-19 vaccine

One of the world’s leading vaccine manufacturers has suffered a major setback in its work to produce a Covid-19 vaccine. The problem will push the timeline for deployment of Sanofi Pasteur’s vaccine — if it is approved — from the first half of 2021 into the second half of the year, the company said Friday.

The news is not just disappointing for Sanofi and its development partner, GlaxoSmithKline, which is providing an adjuvant used in the vaccine. The companies have contracts with multiple countries, including the United States and Britain, as well as the European Union.

https://www.statnews.com/2020/12/11/sanofi-suffers-major-setback-in-development-of-a-covid-19-vaccine/

Sanofi suffers major setback in development of a Covid-19 vaccine

One of the world’s leading vaccine manufacturers has suffered a major setback in its work to produce a Covid-19 vaccine. The problem will push the timeline for deployment of Sanofi Pasteur’s vaccine — if it is approved — from the first half of 2021 into the second half of the year, the company said Friday.

The news is not just disappointing for Sanofi and its development partner, GlaxoSmithKline, which is providing an adjuvant used in the vaccine. The companies have contracts with multiple countries, including the United States and Britain, as well as the European Union.

https://www.statnews.com/2020/12/11/sanofi-suffers-major-setback-in-development-of-a-covid-19-vaccine/

https://www.theedgemarkets.com/article/esg-issues-weigh-top-gloves-valuations

Interesting... thanks for sharing

@noobie123 don’t forget even Johnson and Johnson vaccine trial was halted due to serious side effects but eventually allowed to proceed after further investigations by regulators concluded that there was no strong causal relationship between the vaccine and the serious side effect

Exactly, but they allowed the trial to proceed after further investigations as western regulators concluded that there is no strong causal relationship between the negative event and the vaccine...

Also take into account that sinopharm vaccine has been used in more than 1 million people without serious side effects . Hence , based on that fact , the frequency of serious side effects of sinopharm is still much much much lower than western vaccines such as Pfizer , Moderna and AstraZeneca vaccine considering the number of subjects that have been vaccinated with western vaccines...

@ravx

1) Firstly, it is standard procedure to halt a clinical trial when ANY serious negative event has been reported in the clinical trials regardless of whether there is any causal realtionship. This is to allow regulators to investigated analyse the cause of the event to determine whether there is a strong causal link between the vaccine and the negative event. Case in point, Sinovac vaccine trial was quite recently halted due to death of a volunteer when the volunteer death has got nothing to do with the vaccine. The volunteer COMMITTED SUICIDE. Needless to say, the trial was allowed to resume after the investigation.

2) As regulators we are fully aware about all these reported side effects of Covid vaccines.
However, one must take into account the expected background rate or frequency of the event in the general population in order to conclude whether there is causal relationship or not.
This was why FDA proceeded to grant authorization to Pfizer vaccine just yesterday despite reports of Bell's palsy in 4 volunteers who were vaccinated simply because "The observed frequency of reported Bell’s palsy in the vaccine group is consistent with the expected background rate in the general population, and there is no clear basis upon which to conclude a causal relationship". See information below for further information.

3) Likewise, in this case ONLY 1 volunteer was reported to have Guillain-Barre syndrome. So it is too early to conclude anything until further investigations.

---------------------

Vaccines and Related Biological Products Advisory Committee Meeting
December 10, 2020
FDA Briefing Document
Pfizer-BioNTech COVID-19 Vaccine

Among non-serious unsolicited adverse events, there was a numerical imbalance of four cases of Bell’s palsy in the vaccine group compared with no cases in the placebo group, though the four cases in the vaccine group do not represent a frequency above that expected in the general population.

Bell’s palsy was reported by four vaccine participants and none in the placebo group. These cases occurred at 3, 9, 37, and 48 days after vaccination. One case (onset at 3 days postvaccination) was reported as resolved with sequelae within three days after onset, and the other three were reported as continuing or resolving as of the November 14, 2020 data cut-off with ongoing durations of 10, 15, and 21 days, respectively. The observed frequency of reported Bell’s palsy in the vaccine group is consistent with the expected background rate in the general population, and there is no clear basis upon which to conclude a causal relationship at this time, but FDA will recommend surveillance for cases of Bell’s palsy with deployment of the vaccine into larger populations.

Bell’s palsy
was reported by four vaccine participants. From Dose 1 through 1 month after Dose 2, there
were three reports of Bell’s palsy in the vaccine group and none in the placebo group. This
observed frequency of reported Bell’s palsy is consistent with the expected background rate in
the general population. There were no other notable patterns or numerical imbalances between
treatment groups for specific categories of non-serious adverse events (including other
neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship
to BNT162b2 vaccine.

From Dose 1 through 1 month after Dose 2, there
were three reports of Bell’s palsy in the vaccine group and none in the placebo group. This
observed frequency of reported Bell’s palsy is consistent with the expected background rate in
the general population. There were no other notable patterns or numerical imbalances between
treatment groups for specific categories of non-serious adverse events (including other
neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship
to BNT162b2 vaccine.

This observed frequency of reported Bell’s palsy is consistent with the expected background rate in
the general population. There were no other notable patterns or numerical imbalances between
treatment groups for specific categories of non-serious adverse events (including other
neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship
to BNT162b2 vaccine.

Although the safety database revealed
an imbalance of cases of Bell’s palsy (4 in the vaccine group and none in the placebo group),
causal relationship is less certain because the number of cases was small and not more
frequent than expected in the general population. Further signal detection efforts for these
adverse events will be informative with more widespread use of the vaccine.

https://www.fda.gov/media/144245/download

Bursa Malaysia is expected to trend higher next week

https://www.malaymail.com/news/money/2020/12/12/bursa-malaysia-is-expected-to-trend-higher-next-week/1931258

----------------

Bursa Malaysia expected to break 1,700 psychological level

Bursa Malaysia is expected to trend higher next week, with the key FTSE Bursa Malaysia KLCI (FBM KLCI) breaking the psychological level of 1,700, and poised to march into the new year with a big bang.

https://themalaysianreserve.com/2020/12/12/bursa-malaysia-expected-to-break-1700-psychological-level/

Bursa Malaysia is expected to trend higher next week

https://www.malaymail.com/news/money/2020/12/12/bursa-malaysia-is-expected-to-trend-higher-next-week/1931258

----------------

Bursa Malaysia expected to break 1,700 psychological level

Bursa Malaysia is expected to trend higher next week, with the key FTSE Bursa Malaysia KLCI (FBM KLCI) breaking the psychological level of 1,700, and poised to march into the new year with a big bang.

https://themalaysianreserve.com/2020/12/12/bursa-malaysia-expected-to-break-1700-psychological-level/

Bursa Malaysia is expected to trend higher next week

https://www.malaymail.com/news/money/2020/12/12/bursa-malaysia-is-expected-to-trend-higher-next-week/1931258

----------------

Bursa Malaysia expected to break 1,700 psychological level

Bursa Malaysia is expected to trend higher next week, with the key FTSE Bursa Malaysia KLCI (FBM KLCI) breaking the psychological level of 1,700, and poised to march into the new year with a big bang.

https://themalaysianreserve.com/2020/12/12/bursa-malaysia-expected-to-break-1700-psychological-level/

Bursa Malaysia is expected to trend higher next week

https://www.malaymail.com/news/money/2020/12/12/bursa-malaysia-is-expected-to-trend-higher-next-week/1931258

----------------

Bursa Malaysia expected to break 1,700 psychological level

Bursa Malaysia is expected to trend higher next week, with the key FTSE Bursa Malaysia KLCI (FBM KLCI) breaking the psychological level of 1,700, and poised to march into the new year with a big bang.

https://themalaysianreserve.com/2020/12/12/bursa-malaysia-expected-to-break-1700-psychological-level/

Bursa Malaysia is expected to trend higher next week

https://www.malaymail.com/news/money/2020/12/12/bursa-malaysia-is-expected-to-trend-higher-next-week/1931258

----------------

Bursa Malaysia expected to break 1,700 psychological level

Bursa Malaysia is expected to trend higher next week, with the key FTSE Bursa Malaysia KLCI (FBM KLCI) breaking the psychological level of 1,700, and poised to march into the new year with a big bang.

https://themalaysianreserve.com/2020/12/12/bursa-malaysia-expected-to-break-1700-psychological-level/

Bursa Malaysia is expected to trend higher next week

https://www.malaymail.com/news/money/2020/12/12/bursa-malaysia-is-expected-to-trend-higher-next-week/1931258

----------------

Bursa Malaysia expected to break 1,700 psychological level

Bursa Malaysia is expected to trend higher next week, with the key FTSE Bursa Malaysia KLCI (FBM KLCI) breaking the psychological level of 1,700, and poised to march into the new year with a big bang.

https://themalaysianreserve.com/2020/12/12/bursa-malaysia-expected-to-break-1700-psychological-level/

Bursa Malaysia is expected to trend higher next week

https://www.malaymail.com/news/money/2020/12/12/bursa-malaysia-is-expected-to-trend-higher-next-week/1931258

----------------

Bursa Malaysia expected to break 1,700 psychological level

Bursa Malaysia is expected to trend higher next week, with the key FTSE Bursa Malaysia KLCI (FBM KLCI) breaking the psychological level of 1,700, and poised to march into the new year with a big bang.

https://themalaysianreserve.com/2020/12/12/bursa-malaysia-expected-to-break-1700-psychological-level/